A social media leak torched Moderna's credibility before the science even had its say

Moderna shares lost as much as a quarter of their value Thursday after partial data from its Phase 3 melanoma vaccine trial with Merck surfaced on social media ahead of a scheduled conference presentation this weekend, erasing roughly $24 billion in market value in a single session.

The brutal irony is that the full trial results have not yet been officially released, meaning the market punished Moderna for a leak, not a verdict - a sign of how fragile sentiment around the stock had become after months of gains.

Two storage and chip stocks beat earnings and fell hard, exposing a trust gap between results and guidance

Western Digital posted a blowout quarter with $1.78 billion in profit, topping Wall Street on both revenue and earnings, and Bloom Energy raised its full-year outlook after strong results driven by AI data center power demand, yet both companies beat expectations and still saw their shares fall sharply on the day.

When a company beats estimates and the stock still sells off, the market is saying it doesn't believe the good times will last - investors are looking past this quarter and worrying about whether pricing holds and whether the AI-driven demand surge is as durable as management claims.

Apple's foldable phone launch resets the terms of a market Samsung has owned for years

Apple unveiled the iPhone Duo on Friday, its first foldable device and the most significant departure from its standard smartphone design in nearly two decades, while separately a court in Australia ordered the company to reopen its App Store to Epic Games' Fortnite after finding it had broken competition law.

The foldable launch matters less as a single product and more as a signal that Apple has decided the form factor is finally ready for its mainstream audience - when Apple enters a category, it tends to define it, not just join it.